Simtra BioPharma Solutions, a CDMO specializing in injectable medicines, reports that it has purchased a 65-acre property in Bloomington, Indiana, with more than 300,000 square feet of available space for expansion under-roof near its existing manufacturing facility in Bloomington. The company says that the move is part of a strategy to increase its manufacturing footprint in the US.  

Simtra is evaluating a project to design and install manufacturing lines at the site in Bloomington, including the company’s first US-based commercial-scale capacity for oncology-focused injectable drug products. The facility would run isolator-based vial and prefilled syringe filling lines.  

This purchase complements other previously announced investments in the company’s growth, including a $250-million construction project currently underway at Simtra’s existing Bloomington manufacturing site, and the recently completed $100+ million new production building and $14-million conjugation and purification suite being built in Halle/Westfalen, Germany.  

For the expansion at the new property in Bloomington, Simtra says it will work with Monroe County, Indiana officials on a phased development plan, and the Company will share additional details in the coming weeks (as reported on July 25, 2025). 

Source: Simtra BioPharma Solutions